Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glycemic Variability Predicts Major Adverse Cardiac Event

By LabMedica International staff writers
Posted on 19 Mar 2019
Major adverse cardiovascular events (MACE) are a composite endpoint frequently used in cardiovascular studies, comparable to the composite endpoint all-cause mortality. Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.

Acute glucose fluctuations are associated with hypoglycemia and are emerging risk factors for cardiovascular outcomes. However, the relationship between glycemic variability (GV) and the occurrence of midterm MACE in patients with diabetes remains unclear. A glycemic variability cutoff value could be the strongest independent predictive factor for midterm MACE in patients with diabetes and acute coronary syndrome.

Medical scientists at the Centre Hospitalier Universitaire de Bordeaux (Bordeaux, France) and their colleagues investigated the relationship between glycemic variability and the occurrence of midterm MACE. The team assessed glycemic variability in 327 consecutive patients (mean age, 69 years) hospitalized with diabetes and acute coronary syndrome. Each patient was evaluated for glycemic variability at enrollment and was monitored during follow-up for such major cardiovascular events as new-onset myocardial infarction, acute heart failure, and cardiac death.

The investigators reported that of the study population, 89 (27.2%) people experienced a major cardiovascular event during a mean follow-up of 16.9 months; 24 patients died of cardiac causes, 35 had new-onset myocardial infarction, and 30 were hospitalized because of acute heart failure. Using multivariable logistic regression analysis, they found multiple independent predictive factors of midterm major cardiovascular events, including a glycemic variability value greater than 2.7 mmol/L (odds ratio [OR] = 2.21); a synergy between Percutaneous Coronary Intervention (PCI) with Taxus and Cardiac Surgery score greater than 34 (OR = 1.88), and reduced ventricular ejection fraction of less than 40%. A Global Registry of Acute Coronary Events risk score greater than 140 was not predictive (OR = 1.07).

The authors concluded that a GV cutoff value of greater than 2.70 mmol/L was the strongest independent predictive factor for midterm MACE in patients with diabetes and acute coronary syndrome. The study was published in the February 2019 issue of the journal Diabetes Care.

Related Links:
Centre Hospitalier Universitaire de Bordeaux


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.